Syncom Formulations (India) Ltd

SYNCOM Formulations (India) Limited submitted a certificate to the BSE Limited and National Stock Exchange of India Limited for compliance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026, as confirmed by its Registrar and Share Transfer Agent, Ankit Consultancy Pvt. Ltd.

Syncom Formulations (India) Limited announced that its members approved a final dividend of Rs 0.10 (10%) per equity share on 94,00,00,000 equity shares for the financial year 2025-26 at its 38th Annual General Meeting held on Wednesday, September 30, 2026.

Syncom Formulations (India) Limited announced that its shareholders approved the appointment of Rahul Vijay Bankda as Managing Director, effective August 12, 2026, and Rinki Ankit Bankda as Whole Time Director, also effective August 12, 2026. Additionally, the company re-appointed Ruchi Jindal as an Independent Woman Director for a second five-year term, effective June 28, 2027.

Syncom Formulations (India) Limited informed the Bombay Stock Exchange and National Stock Exchange that its Promoters and Promoter Group have voluntarily waived their entitlement to receive the final dividend of Rs 0.10 per equity share for the financial year ended March 31, 2026, representing a total of Rs 4,75,34,759.90, out of the company’s 94,00,00,000 outstanding equity shares, of which 47,53,47,599 shares are held by the Promoters and Promoter Group.

Syncom Formulations (India) Limited informed the Bombay Stock Exchange and National Stock Exchange that the trading window for its shares will be closed from October 1, 2026, until 48 hours after the declaration of the company’s unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, in compliance with SEBI regulations. The company will also notify CDSL, the designated depository, two trading days prior to the window closure, and promoters, directors, key managerial personnel, designated persons, connected persons, and their immediate relatives are prohibited from trading during this period.

Syncom Formulations (India) Limited has fixed Wednesday, September 23, 2026, as the record date for determining the entitlement of members for a dividend of Rs 0.10 per equity share for the financial year 2025-26, subject to shareholder approval at the company’s 38th Annual General Meeting to be held on Wednesday, September 30, 2026, via video conferencing or other audio-visual means. Shareholders who wish to waive their dividend entitlement are requested to submit a completed form to the company or its registrar and transfer agent, Ankit Online, by September 26, 2026.

Syncom Formulations (India) Limited announced changes to its board and senior management, effective August 11, 2026. The company said Kedarmal Shankarlal Bankda and Vijay Shankarlal Bankda resigned from their respective positions as Whole-time Director and Managing Director, while Rahul Vijay Bankda resigned as Chief Financial Officer. Subsequently, Rinki Ankit Bankda was appointed as Additional Director and Whole Time Director, Rahul Vijay Bankda as Additional Director and Managing Director, and Ankur Vijay Bankda as Chief Financial Officer, all subject to shareholder approval at the upcoming Annual General Meeting. Additionally, Smt. Ruchi Jindal was reappointed as Woman Independent Director, effective June 29, 2027, also pending shareholder approval.

Syncom Formulations (India) Limited has fixed Wednesday, September 23, 2026, as the record date for determining entitlement to a dividend of Rs. 0.10 per equity share, representing 10% for the financial year ended March 31, 2026, subject to shareholder approval at the company’s 38th Annual General Meeting to be held on Wednesday, September 30, 2026, at 2:00 P.M. via video conferencing or other audio-visual means.

SYNCOM Formulations (India) Limited will hold a board meeting on Tuesday, August 11, 2026, at 4:00 P.M. (IST) to consider and approve the standalone and consolidated unaudited financial results for the quarter ended June 30, 2026, and to take on record the limited review report by auditors, as well as to consider a final dividend recommendation for the financial year ended March 31, 2026.

SYNCOM Formulations (India) Limited will hold a board meeting on Tuesday, August 11, 2026, at 4:00 P.M. (IST) to consider and approve the standalone and consolidated unaudited financial results for the quarter ended June 30, 2026, and to take on record the limited review report by auditors, as well as to consider a final dividend recommendation for the financial year ended March 31, 2026.